Overview

Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

Status:
Terminated

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this research is to determine the effectiveness of CGC-11047 in subjects with metastatic hormone refractory prostate cancer as measured by changes in PSA.

Phase:

Phase 2

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborator:

Progen Pharmaceuticals

Treatments:

Hormones